studi
evalu
diagnost
potenti
clinic
impact
autom
multiplex
pcr
platform
filmarray
respiratori
panel
farp
special
design
pathogen
detect
respiratori
tract
infect
adult
unexplain
pneumonia
sever
acut
respiratori
syndrom
outbreak
order
track
similarli
highli
contagi
sever
lower
respiratori
ill
pneumonia
symptom
chines
govern
paid
great
attent
unexplain
pneumonia
phrase
coin
chines
human
unexplain
pneumonia
surveil
network
chupsn
publish
refer
pneumonia
could
lifethreaten
character
rapid
progress
normal
white
blood
cell
count
rang
poor
respons
antibiot
although
common
pathogen
caus
virus
atyp
pathogen
overlap
clinic
manifest
imped
abil
clinician
directli
diagnos
caus
pathogen
may
lead
unnecessari
antimicrobi
usag
thu
rapid
precis
diagnosi
caus
agent
critic
prompt
manag
date
culturebas
tradit
method
use
help
clinic
approach
diagnos
howev
method
certain
disadvantag
exampl
rapid
antigen
test
sensit
adult
influenza
depend
use
specif
scientif
techniqu
wherea
cultur
virus
take
day
recent
year
increas
use
nucleic
acid
amplif
test
naat
base
method
detect
viral
pathogen
due
excel
diagnost
abil
identifi
broad
spectrum
pathogen
prospect
cohort
enrol
shanghai
china
within
hour
patient
admiss
respiratori
tract
specimen
collect
includ
bronchoalveolar
lavag
fluid
balf
among
patient
gave
consent
undergo
bronchoscopi
sputum
expector
evid
nasopharyng
swab
np
bronchoscopi
perform
expector
sampl
collect
notabl
lower
respiratori
tract
specimen
given
higher
prioriti
balf
sputum
np
studi
soon
possibl
sampl
specimen
transfer
laboratori
infecti
diseas
research
institut
huashan
hospit
shanghai
profession
pulmonari
physician
oversaw
balf
sampl
collect
np
sputum
perform
clinic
physician
per
clinic
standard
oper
procedur
notabl
sampl
np
balf
viscos
low
requir
sampl
prepar
filmarray
panel
test
wherea
viscou
sampl
sputum
pretreat
use
previous
describ
dunk
swirl
method
remain
specimen
store
freezer
use
studi
use
version
farp
autom
multiplex
pcr
detect
platform
design
detect
common
pathogen
caus
respiratori
infect
singl
specimen
turnaround
time
hour
test
use
panel
perform
follow
manufactur
instruct
specimen
farp
report
influenza
sub
patient
group
tradit
standardofcar
laboratori
diagnost
test
respiratori
infect
perform
accord
request
physician
includ
smear
cultur
serolog
test
serolog
test
studi
pneumoslid
igm
vircel
commerci
kit
base
indirect
immunofluoresc
studi
clinic
data
includ
antimicrobi
use
adjust
deescal
antimicrobi
therapi
compar
farp
group
retrospect
control
group
turnaround
time
defin
length
time
sampl
collect
receiv
farp
result
antimicrobi
use
quantifi
defin
daili
dose
ddd
number
calcul
drug
total
dosag
g
drug
ddd
index
adjust
antimicrobi
therapi
defin
chang
antimicrobi
regimen
immedi
receiv
farp
result
overview
patient
enrol
workflow
total
patient
select
prospect
submit
farp
analys
refer
farp
group
lost
followup
complet
data
refer
intervent
group
comparison
made
histor
control
group
mannwhitney
u
test
use
comparison
quantit
data
spss
ibm
use
data
analys
use
graphpad
draw
graph
ethic
committe
huashan
hospit
shanghai
approv
studi
juli
particip
gave
written
inform
consent
tabl
mix
infect
multipl
pathogen
detect
six
patient
influenza
virusrsv
n
influenza
virushuman
metapneumoviru
n
influenza
n
pneumoniaehuman
rhinovirusenteroviru
n
human
rhinoviru
n
adenoviruscoronaviru
n
sampl
farp
result
influenza
anot
subtyp
case
subtyp
perform
use
realtim
rtpcr
consequ
influenza
viru
subtyp
detect
sampl
remain
two
sampl
consequ
find
fafp
regard
influenza
patient
isol
neg
pressur
ward
singl
ward
includ
seven
highli
pathogen
case
contrast
control
group
compar
isol
measur
undertaken
compar
antimicrobi
use
intervent
control
group
found
two
group
compar
baselin
characterist
tabl
compar
control
group
intervent
group
show
signific
decreas
antimicrobi
ddd
control
group
vs
intervent
group
p
howev
exclud
antivir
drug
detect
significantli
lower
antibioticantifung
ddd
studi
appli
farp
diagnosi
certain
type
pneumonia
caus
mainli
virus
atyp
pathogen
found
farp
detect
pathogen
specimen
higher
detect
rate
obtain
techniqu
appli
gener
communityacquir
pneumonia
result
therefor
show
appli
clinic
farp
would
provid
higher
probabl
identifi
causal
pathogen
microorgan
present
studi
found
patient
farp
group
receiv
antivir
treatment
significantli
higher
control
group
random
control
trial
discov
use
farp
associ
reduct
overal
durat
antibiot
usag
nevertheless
higher
number
patient
farp
group
receiv
singl
dose
brief
cours
antibiot
control
group
given
inconclus
find
studi
requir
concern
impact
farp
clinic
decis
regard
pneumonia
compar
durat
hospit
stay
two
group
result
intervent
group
unexpectedli
show
longer
durat
hospit
stay
control
group
vs
day
p
one
reason
explan
subject
intervent
group
sever
case
pneumonia
control
group
higher
psi
present
studi
one
sever
examin
applic
farp
asia
compar
publish
studi
studi
focus
adult
sever
pneumonia
condit
best
knowledg
studi
studi
howev
limit
notabl
sampl
size
limit
studi
conduct
singl
locat
may
thu
limit
gener
applic
find
addit
studi
includ
two
cohort
differ
time
period
henc
may
differ
factor
influenc
clinician
behavior
two
period
account
analysi
furthermor
incid
variou
respiratori
virus
may
vari
across
two
period
may
thu
limit
valid
direct
comparison
clinic
outcom
conclus
farp
rapid
sensit
naat
method
use
diagnosi
adult
two
recent
year
shanghai
common
pathogen
caus
identifi
influenza
viru
howev
regard
taken
consider
current
version
farp
unabl
directli
detect
nevertheless
result
obtain
studi
show
farp
may
make
valuabl
contribut
clinic
decis
make
facilit
reason
use
antibiot
would
like
thank
yinlei
zhang
traci
wang
xuyang
wang
xinchang
chen
substanti
contribut
studi
yiyi
qian
http
